# StrokeNET Webinar Grant Writing

Steven M. Greenberg, MD, PhD Harvard Medical School Massachusetts General Hospital

August 16, 2016



#### **Grant Writing**

- 1. Overview of Patient-Based Research
- 2. A Reviewer's Thought Process
- 3. Considerations for NIH StrokeNet

#### **Grant Writing**


- 1. Overview of Patient-Based Research
- 2. A Reviewer's Thought Process
- 3. Considerations for NIH StrokeNet

# Why would anyone study human disease in humans?

- In vitro systems are flexible and elegant
- Wide range of available pharmacologic or genetic manipulations
- A lot easier to order a vial of cells or a colony of mice than a cohort of patients

#### ...especially neurologic disease?

- Difficulty acquiring CNS tissue
- Blood-brain barrier to both influx and efflux



Copyright © 2005 Nature Publishing Group Nature Reviews | Neuroscience

#### Strengths of Patient-Based Research

- Studying humans means studying the disease, not the disease model
- New findings increasingly flow not just bench to bedside, but also bedside to bench

"Scientists are increasingly aware that [the] bench-to-bedside approach to translational research is really a two-way street...."

-NIH Roadmap for Medical Research "Reengineering the Clinical Research Enterprise"

# THINK GLOBALLY ACT LOSALLY Peace Resource Project 888-822-7075 www.peaceproject.com MS#10)

Clinically

#### 1. Define compelling biological questions

- No unimportant question is worth answering
- What unknowns stand between where we are and where we need to be?
- Which are accessible to current technology?
- One eye on clinical translation, other on underlying pathogenesis

- 1. Define compelling biological questions
- Identify potential bedside-to-bench methodologies
  - Neuroimaging (structural, functional, molecular)
  - Biomarkers (beware of cause vs effect issue)

- 1. Define compelling biological questions
- Identify potential bedside-to-bench methodologies
- 3. Collaborate widely and generously
  - Impossible to "go it alone" in clinical research
  - Durable collaboration meets everyone's needs (\$'s, publication credit, shared personnel, training, samples, friendship)

- 1. Define compelling biological questions
- Identify potential bedside-to-bench methodologies
- 3. Collaborate widely and generously
- 4. Get your own patients
  - Sample size projection is inherently shaky, but...
  - Natered is worth recinquestance between the detect something
    - i.e. No one loves your study as much as you

- 1. Define compelling biological questions
- Identify potential bedside-to-bench methodologies
- 3. Collaborate widely and generously
- 4. Get your own patients
- 5. Don't lose hope
  - NIH funding is cyclical
  - Special paylines for NI/ESI

#### **Grant Writing**

- 1. Overview of Patient-Based Research
- 2. A Reviewer's Thought Process
- 3. Considerations for NIH StrokeNet

#### Classes of NIH Grants

- 1. R Series Awards
  - R01 "research project"
  - R03 "small project" (\$100K /2 yrs)
  - R21 "exploratory/developmental" (\$275K /2 yrs)

#### **Review Clusters**

- Cluster A = R01 from established investigators
- Cluster B = R01 from New or Early Stage PI
  - New Investigator = not previously competed successfully as PD/PI for a substantial NIH independent research award
  - Early Stage Investigator = New Investigator within 10 years of last degree or residency
- Cluster C/D = R03 and R21

#### R Series Awards

- Significance
- Investigator
- Innovation
- Approach
- Environment

Overall Impact

- 1. Does the question need to be answered?
- 2. Can this applicant answer it?
- 3. Are the studies feasible?

- 1. Does the question need to be answered?
  - Scored as Significance
  - Not sufficient to state that disease X is common, devastating, and untreatable. Your specific question needs to have impact.
  - Established largely by Specific Aims, reinforced by Significance

- 1. Does the question need to be answered?
- 2. Can this applicant answer it?

#### Productivity of investigative team

- Scored as Investigator
- Publications (number, quality, relevance)
- Record of similar projects
- Co-Investigators can inoculate from some critiques...but ultimately rests on PI


- 1. Does the question need to be answered?
- 2. Can this applicant answer it?

#### Power and Elegance of Proposed Techniques

- Straightforward appropriateness (Approach)
- Elegance, novelty, "sparkle" (Innovation)
- Reviewer's impression largely driven by preliminary data (not required for R03/R21)

- 1. Does the question need to be answered?
- 2. Can this applicant answer it?
- 3. Are the studies feasible?
- Ability to meet targeted recruitment (Approach, Environment)
- Soundness of sample size estimate (Approach)
- Inclusion of women, minorities, children, especially for phase 3 (Approach, Environment)
- Hard to gain points in Approach, easy to lose

#### Variability of R criterion scores



- 1. Does the question need to be answered?
- 2. Can this applicant answer it?
- 3. Are the studies feasible?
- Every sentence in your proposal should help reviewer answer "Yes!"
- Reviewer begins to form impression at the Abstract, certainly at the Biosketch and Specific Aims.

#### Phrases in a R01 review

- Ones you want to hear
  - compelling, exciting
  - nationally/internationally recognized team
  - state-of-the-art techniques
- Ones you don't
  - incremental, descriptive
  - speculative, overly ambitious
  - contingent (if SA1 fails, whole grant fails)
- Range from solid SA1 to exciting SA3

#### New emphasis areas (2016-) Rigor and reproducibility

- Scientific premise (Significance)
- Scientific rigor (Approach)
- Biological variables (Approach)
  - > e.g. sex, age, weight, comorbidities
- Authentication (other)

### A Reviewer's Thought Process Personal reflections

- Writing clarity/style matter
- Small factual or conceptual errors matter (unfortunately)
- Reputation matters (unfortunately)
- Who reviews your grant matters...but unpredictably
- NEVER attempt to tamper with review

#### Classes of NIH Grants

- 1. R Series Awards
- 2. K08/K23 Awards
  - Typically 75% effort
  - Modest additional funds, e.g. coursework, part of a research assistant

#### R Series

#### K Series

- Significance
- Investigator
- Innovation
- Approach

- Candidate
- Career Development Plan
- Research Plan
- Mentor
- Environment = Environment/Institutional Commitment

- 1. Is the applicant a winner?
- 2. Can the mentor move the applicant to independence?
- 3. Will the research move the applicant to independence?

- 1. Is the applicant a winner?
  - Obviously subjective
  - Publications, national/international presentations, applicant-generated preliminary data
  - Letters of support (mentor, referees, institution)
  - Quality of research plan

- 1. Is the applicant a winner?
- 2. Can the mentor move the applicant to independence?

#### Ideal mentor

- Productive
- Senior enough to expose applicant nationally
- Nurturing
- Established by track record of previous trainees, level of commitment in letter

- 1. Is the applicant a winner?
- 2. Can the mentor move the applicant to independence?
- 3. Will the research move the applicant to independence?
- Intrinsic impact of plan less important than capacity for moving applicant to his/her R01
- An unfeasible plan (lack of resources, expertise, subjects) is a poor training vehicle


### K Overall Impact Other Elements

Handle comprehensively and methodically

- Didactic training (e.g. biostatistics)
- Training in responsible conduct of research
- Institutional support
- Unconditional guarantee of protected time
- Like Approach in R01: Hard to gain points, easy to lose.

#### **Grant Writing**

- 1. Overview of Patient-Based Research
- 2. A Reviewer's Thought Process
- 3. Considerations for NIH StrokeNet





#### NIH StrokeNet

- "The primary goal of this network is to maximize efficiencies to develop, promote, and conduct high-quality trials focused on key interventions in stroke prevention, treatment and recovery."
- Funding mechanisms
  - U01
  - X01 (Infrastructure access for industry)
  - U44 (Funding for small business)

# StrokeNet Types of trials

- Multicenter only (≥5 sites)
- Stroke patients, not healthy volunteers
- Primary/secondary prevention, acute treatment, or recovery/rehabilitation
- Exploratory phase 1/2 (dose finding, safety, target engagement, technique), phase 2/3 transition, phase 3 confirmatory
- Biomarker/PK/outcome validation (if immediately preparatory to trial)

# NIH StrokeNet Process for proposals

- Concept synopsis reviewed for completeness/appropriateness (NINDS staff), alignment with mission/priorities (ESC)
- Executive/working committees review feasibility
  - Availability of patients (GCNKSS)
  - Willingness/ability of sites to participate
  - Availability of drug, etc
- If approved, PI writes proposal with input/letters from StrokeNet

# StrokeNet Dispelling misconceptions

- StrokeNet doesn't fund your trial
  - The network delivers the sites, the local support (dedicated site PI, fellow, coordinator), the cIRB and MCTA structures, and the imprimatur
- StrokeNet doesn't fund your grant
  - U01 proposals peer reviewed by NINDS special emphasis panel
- StrokeNet doesn't write your grant
  - But working groups may help you develop your concept for your U01

### A Reviewer's Thought Process Considerations for StrokeNet

- 1. Does the question need to be answered?
  - Address unmet need
  - Unravel biological mechanism
  - Provide crucial information for phase 3 study
- 2. Can this applicant answer it?
  - StrokeNet brand very helpful here
- 3. Are the studies feasible?
  - Stroke trials have history of underrecruitment, too many exclusions, too intricate protocol
  - Safety, analytic plan also key



"Mr. Osborne, may I be excused? My brain is full."

